Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older.

Trial Profile

Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Nov 2009 Results have been reported by GlaxoSmithKline in a media release.
    • 06 Oct 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top